Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Explosive growth : 9 largecap stocks with stellar YoY sales gains
3/10/2025
Gold snaps 5-day record rally ; falls Rs 500 to Rs 1,20,600/10 g in Delhi
3/10/2025
Metal stocks rally ; Lloyds Metals jumps over 6%, Tata Steel up more than 3%
3/10/2025
Nifty shows positive reversal ; experts eye buying opportunities on dips
3/10/2025
This smallcap stock hits 20% upper circuit for 2nd session after bagging mega order
3/10/2025
Earnings momentum, banks and discretionary consumption to drive market upside : Tushar Bohra
3/10/2025
